Treating Multiple Sclerosis

Developing a novel treatment for Multiple Sclerosis.
A hope for the millions of sufferers and their carers.


Neuvene™ (Lynflexine™), is a first-in-class drug candidate with disease modifying potential for the treatment of relapsing remitting and progressive forms of multiple sclerosis and for the treatment of neurodegeneration following concussion.

multiple sclerosis treatment
Millions of sufferers

There are now 2.8 million people worldwide who have multiple sclerosis according to the National MS society of the US.

novel drug multiple sclerosis
A huge cost to society

The estimated total economic burden of MS just in the US is estimated at $85.4 billion. Neurology May 2022.

novel treatment multiple sclerosis
A debilitating disease on the rise

The global prevalence of MS has risen since 2013 as published in Insights from the Atlas of MS.

Multiple Sclerosis

Multiple sclerosis (MS) is an autoimmune disease affecting principally the central nervous system that causes nerve sheath demyelination followed by axon damage and paralysis. MS symptoms include muscle weakness, weak reflexes, tremor, muscle spasm, prolonged double vision, slurred speech, and lack of coordination or unsteady gait. MS can occur at any age, but commonly affects people of ages 15–60 years. MS symptoms may occur and disappear completely, while the permanent neurological problems occur when the disease advances (Mayo Clinic, 2019).

The diagnosis of MS depends upon the patient symptoms, magnetic resonance imaging (MRI), and laboratory results, but it is mostly diagnosed in the late phases. Presently, MS is diagnosed by the widely used McDonald criteria, which is a combination of laboratory, clinical, and radiology reports of lesions at different times in different body areas (Lublin, 2014). Currently, there is no cure for MS. However, treatments can help speed recovery from attacks, modify the course of the disease, and manage symptoms (Mayo Clinic, 2019).

multiple sclerosis drug development

Exciting mechanism

Novel nasal formulation of relaxin, activating GR and RXFP1 with protective effects.

A natural hormone

A human hormone, potential as a treatment for MS underpinned by scientific rationale.


An new and unique mechanism of action to treat multiple sclerosis

Low Risk

Relaxin's targets are known and the molecule is naturally occurring in the body.

Excellent safety

Because the molecule is a human hormone, it is expected to have an excellent safety profile.

Ample evidence

The preclinical results are supported by the known improvement in MS patients during pregnancy.

Neuvene™ (Lynflexine™) - a new treatment for MS

in development targeting Multiple Sclerosis, and other CNS indications. It has the potential to modulate the clinical symptoms of MS, be neuroprotective and promote remyelination.


Our passion, commitment and focus

A target product profile which is second to none

Neuvene™ is expected to be a safe and effective treatment in a convenient nasal spray formulation. It is being developed as a therapy for acute attacks in multiple sclerosis; relapsing remitting and chronic forms of multiple sclerosis; neurodegeneration caused by concussion and/or traumatic brain injury.

Learn more
cns biotech company developing pharmaceuticals for neurological diseases